Two new families of pyrazoline and thiadiazoline heterocycles have been developed. Their inhibitory activities against two different isoforms of nitric oxide synthase (inducible and neuronal NOS) are reported. The novel derivatives were synthesized combining the arylthiadiazoline or arylpyrazoline skeleton and a carboxamide or carbothioamide moiety, used as starting material ethyl 2-nitrobenzoates or substituted nitrobenzaldehydes, respectively. The structure-activity relationships of final molecules are discussed in terms of the R 1 radical effects in the aromatic ring, the Y atom in the heterocyclic system, the X heteroatom in the main chain, and the R 2 substituent in the carboxamide or carbothioamide rest. In general, thiadiazolines ( a-e) inhibit preferentially the neuronal isoform; among them, a is the best nNOS inhibitor (74.11% at 1 mM, IC 50 = 420 M). In contrast, pyrazolines ( a-r) behave better as iNOS than nNOS inhibitors, m being the best molecule of this series (76.86% at 1 mM of iNOS inhibition, IC 50 = 130 M) and the most potent of all tested compounds.
Introduction
Heterocyclic rings having two or three heteroatoms in their skeleton have been widely described as part of pharmacological agents with interesting therapeutic applications. In this way, thiadiazoline system is part of structures with antileishmanial activity [1] , as well as antimicrobial [2] , antiinflammatory [2, 3] , anticonvulsant [4] , or antitumoral [5, 6] . In addition, heterocyclic pyrazoline shows a wide spectrum of pharmacological properties such as anticancer [7] [8] [9] , antiinflammatory [10] , anticonvulsant [11, 12] , antimicrobial [13] , antibacterial, antifungal, and antiparasitic [14] . These two types of heterocycles have also been recognized as nitric oxide synthase (NOS) inhibitors that could be useful in neurodegenerative diseases and inflammatory arthritis [15] [16] [17] [18] [19] .
Nowadays, NOS inhibitors represent an important pharmacological group with diverse medical applications since the overproduction of nitric oxide (NO • ) is involved in several pathological processes.
The enzyme NOS catalyzes the conversion of L-arginine (L-arg) in L-citrulline and NO
• , an important molecular messenger involved in several physiological actions in mammals, such as neurotransmission [20] , immune function [21] , or blood flow [22] . Three isoforms of NOS have been identified; two of them are constitutively expressed: neuronal (nNOS), which takes part in neural signaling, and endothelial (eNOS), involved in the systemic blood pressure control and plateled aggregation inhibition; the third isoform, inducible NOS (iNOS), is expressed during immune activation and plays an important role in inflammatory response [23] . Due to its implication in many biological processes, the endogenous synthesis of NO
• is tightly regulated. An overproduction of NO
• by iNOS and nNOS is associated with diverse disorders, such as stroke [24] , migraine [25] , inflammatory arthritis [26] , and various neurodegenerative processes like Parkinson's, Alzheimer's, or Huntington's diseases [27] [28] [29] . Moreover, NO
• produced by stimulation of eNOS plays a physiological role in blood pressure and flow, but its underproduction can cause hypertension [30] . Therefore, the search of selective inhibitors for nNOS or iNOS, but not eNOS, represents an important therapeutic goal since it could help the treatment of diseases in which the first two isoforms are involved.
With this purpose, we have previously described the synthesis and biological evaluation of diverse NOS inhibitors with thiadiazoline [31] and pyrazoline [16, 32] scaffolds, bearing different acyl substituents in the heterocyclic ring. In addition, we have synthesized and evaluated the NOS inhibition of compounds with general structures [33] and [34] (Figure 1 ). These derivatives had more flexible structure containing N,N -disubstituted thiourea and urea rests, isosterics to the terminal guanidine moiety of L-Arg, responsible for the inhibitors binding to the enzyme substrate region; thus it plays an essential role in the enzymatic inhibition [35, 36] .
According to this background, two new families of derivatives containing arylthiadiazoline-based carboxamides and arylpyrazoline-based carboxamides and carbothioamides have been designed and synthesized in this study (Figure 2) . Compounds proceed by mix of the aryl-thiadiazoline fragment present in , and a residue of carboxamide included in and molecules. Additionally, the derivatives have been designed by combination of an aryl-pyrazoline moiety contained in and a residue of carboxamide or carbothioamide, the terminal rest of the previously described derivatives and ( Figure 3 ). All of them have different substituents in the aromatic ring and in the carboxamide or carbothioamide residues in order to perform structure-activity relationship studies. These compounds could be an interesting starting point for possible new alternatives in neurodegenerative or inflammatory disorders.
Experimental

Chemistry
Materials and Methods.
Melting points were determined using an Electrothermal-1A-6301 apparatus and are uncorrected.
1 H NMR and 13 C NMR spectra were recorded on a Varian Inova Unity 300 spectrometer operating at 300. 20 The temperature of the sample was maintained at 297 K. The peaks are reported in ppm ( ). High-resolution mass spectroscopy (HRMS) was carried out on a VG AutoSpec Q high-resolution mass spectrometer (Fision Instruments). Small scale microwaveassisted reactions were performed using an Initiator 2.0 single-mode microwave instrument producing controlled irradiation at 2.450 GHz (Biotage AB, Uppsala). Reaction time refers to holding time at 80 ∘ C, not to total irradiation time. An IR sensor outside the reaction vessel was used to control the temperature. Flash chromatography was carried 
5a-e 6a-r Figure 3 : Design strategy and structure of compounds ( a-e) and ( a-r).
out using silica gel 60, 230-240 mesh (Merk), and the solvent mixture reported within parentheses was used as eluent.
General Procedure for the Synthesis of 2,2-Dimethyl-Nsubstituted-5-(2-nitro-5-phenylsubstituted)-1,3,4-thiadiazole-3(3H)-carboxamide Derivatives (16a-e).
To a solution of the previously described thiadiazole intermediates -(2 mmol) [31] in dry CH 2 Cl 2 , the corresponding isocyanate (3 mmol) and Et 3 N (2 mmol) were added under argon [37] . The reaction mixture was irradiated under microwave conditions at 80 ∘ C for 20 min. The residue was purified by flash chromatography (EtOAc/hexane, 1 : 10). ( a-r) . Thioisocyanate or isocyanate (3 mmol) was added, under argon, to a solution of previously described pyrazole derivatives -(2 mmol) [16] in dry CH 2 Cl 2 and Et 3 N (an equimolar amount) [37] . The reaction mixture was irradiated under microwave conditions at 80 ∘ C for 20 min. The crude mixture was purified by flash chromatography (EtOAc/hexane, 1 : 1). 
2,2-Dimethyl-N-ethyl-5-(2-nitrophenyl
3-(5-Chlorophenyl-2-nitro-)-N-ethyl-4,5-dihydro-1H-pyr-
3-(4,5-Dimethoxy-2-nitrophenyl)-N-ethyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( g)
.), 3.08 (m, 2H, -CH 2 -CH 2 - CH 3 ), 2.93 (t, 2H, H-4, = 10.3 Hz), 1.40 (m, 2H, -CH 2 -CH 2 - CH 3 ), 0.78 (t, 3H, -CH 2 -CH 2 -CH 3 , = 7.4 Hz). 13 C NMR (125.69 MHz, CDCl 3 ): /ppm 155.2 (-CONH-), 152.6 (C-3), 151.6 (C-5 ), 149.3 (C-4 ), 140.7 (C-2 ), 121.8 (C-1 ), 111.7 (C- 6 ), 107.5 (C-3 ), 56.4 (5 -OCH 3 ), 56.3 (4 -OCH 3 ), 45.1 (C-5), 41.6 (-CH 2 -CH 2 -CH 3 ), 34.4 (C-4), 23.3 (-CH 2 -CH 2 -CH 3 ), 11.1 (-CH 2 -CH 2 -CH 3 ). MS (LSIMS): / 337.1527 [M + H] + , Calcd. Mass for C 15 H 21 N 4 O 5 337.1512.
3-(4,5-Dimethoxy-2-nitrophenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide ( i)
.
3-(4,5-Dimethoxy-2-nitrophenyl)-N-ethyl-4,5-dihydro-1H-pyrazole-1-carbothioamide ( j)
.(-CH 2 -CH 2 -CH 3 ), 34.5 (C-4), 22.5 (-CH 2 -CH 2 CH 3 ), 11.4 (-CH 2 -CH 2 -CH 3
3-(6-Nitro-2,3,4-trimethoxyphenyl)-N-propyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( m)
., 3 -OCH 3 , 4 -OCH 3 ), 3.20 (t, H-4, = 10.3 Hz), 3.11 (m, 2H, -CH 2 -CH 2 - CH 3 ), 1.50 (m, 2H, -CH 2 -CH 2 -CH 3 ), 0.91 (t, 3H, -CH 2 -CH 2 - CH 3 , = 7.4 Hz).
3-(6-Nitro-2,3,4-trimethoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( n)
., 3 -OCH 3 , 4 -OCH 3 ), 3.55 (m, 2H, -CH 2 -CH 2 -CH 3 ), 3.19 (t, 2H, H-4, 4-5 = 10.0 Hz), 1.59 (m, 2H, -CH 2 -CH 2 -CH 3 ), 0.91 (t, 3H, -CH 2 -CH 2 -CH 3 , = 7.4 Hz). 13 C NMR (100.73 MHz, CDCl 3 ): /ppm 176.07 (-CSNH-), 154.0 (C-3), 153.4 (C-4 ), 152.2 (C-3 ), 146.7 (C-6 ), 143.2 (C-2 ), 115.8 (C-1 ), 104.2 (C- 5 ), 62.1, 61.2 (2 -OCH 3 , 3 -OCH 3 ), 56.6 (4 -OCH 3 ), 48.6 (C-5), 46.4 (-CH 2 -CH 2 -CH 3 ), 35.9 (C-4), 22.4 (-CH 2 -CH 2 - CH 3 ), 11.3 (-CH 2 -CH 2 -CH 3 ).
General Procedure for the Synthesis of 5-(2-Amino-5-phenylsubstituted)-2,2-dimethyl-N-substituted-1,3,4-thiadiazole-3(3H)-carboxamide Derivatives ( a-e).
To a solution of each nitroarene a-e (0.400 mmol) in ethanol, 453 mg of SnCl 2 was added. The resulting mixture was refluxed for 2 h. After this period, the reaction was neutralized with NaHCO 3 aqueous solution, extracted with AcOEt (2 × 15 ml), and dried with sodium sulfate [38] . Finally, the solvent was evaporated ad the residue was purified by flash chromatography (EtOAc/hexane, 1 : 10) to give the title derivatives a-e. Derivatives ( ar) . Amino-phenyl pyrazolines a-r were prepared according to the same synthetic procedure described before for the thiazodiazoline derivatives a-e. Purification of the final compounds was made using (EtOAc/hexane, 1 : 2) as eluent in the flash chromatography. calmodulin (only for nNOS), and 0,05 M L-[
5-(2-Aminophenyl)-2,2-dimethyl-N-ethyl-1,3,4-thiadiazole-3(2H)-carboxamide ( a).
5-(2-Aminophenyl)-2,2-dimethyl-N-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide ( c)
5-(2-Amino
-5-methoxyphenyl)-2,2-dimethyl-N-ethyl-1,3,4-thia- diazole-3(2H)-carboxamide ( d).
3-(2-Amino-5-chlorophenyl)-N-ethyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( a)
3-(2-Amino-5-chlorophenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( c).
3-(2-Amino-5-methoxyphenyl)-N-ethyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( d)
3-(2-Amino-5-methoxyphenyl)-N-propyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( e)
3-(2-Amino-5-methoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( f)
3-(2-Amino-4,5-dimethoxyphenyl)-N-ethyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( g)
3-(2-Amino-4,5-dimethoxyphenyl)-N-propyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( h)
3-(2-Amino-4,5-dimethoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide ( i)
3-(2-Amino-4,5-dimethoxyphenyl)-N-ethyl-4,5-dihydro-1H-pyrazole-1-carbothioamide ( j).
3-(2-Amino-4,5-dimethoxyphenyl)-N-propyl-4,5-dihydro-1H-pyrazole-1-carbothioamide ( k).
3-(6-Amino-2,3,4-trimethoxyphenyl)-N-propyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( m).
3-(6-Amino-2,3,4-trimethoxyphenyl)-N-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide ( n).
3-(6-Amino-2,3,4-trimethoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide ( o). Brown solid, yield
3-(6-Amino-2,3,4-trimethoxyphenyl)-N-propyl-4,5-dihydro-1H-pyrazole-1-carbothioamide ( q)
3 H]-arginine, at pH 7.6, 10 L of a 10 mM in ethanol solution of each thiadiazoline a-e or pyrazoline a-r derivative, and enough water to reach 100 L. In order to start the reaction, 10 L of a 7.5 mM NADPH was added. NADPH was omitted in control incubations. All the samples were stirred and incubated for 30 minutes at 37 ∘ C. At the end of the incubation, 400 L of a cold solution 0.1 M N-(2-hydroxymethyl)piperazine-N -(2-ethanesulfonic acid) HEPES, 10 mM ethylene glycolbis-(2-aminoethylether)-N,N,N ,N -tetraacetic acid (EGTA), and 0.175 mg/mL L-citrulline at pH 5.5 stopped the reaction. This mixture goes through a column packed with Dowex-50W ion-exchange resin (Na + form) and was eluted with 1.2 mL of water losing around 98% of radioactivity. Finally, 50 L of each sample was diluted with scintillation liquid and the measurements were taken. The nNOS activity was expressed in picomoles of L-[
3 H]-citrulline produced/mg of protein/min.
eNOS Inhibition. Experiments were conducted in male
Wistar rats obtained from Harlan Laboratories (Barcelona, Spain) weighing 200-250 g. The descending thoracic aortic rings were dissected and cut into rings which were mounted in organ chambers by means of two L-shaped stainlesssteel wires inserted into the lumen and attached to the chamber and to an isometric force-displacement transducer coupled to a signal amplifier (Dynamometer UF1, Cibertec, Madrid) and connected to a computer via an A/D interface. Contractile tension was recorded by a Power-Lab 800 (AD Instruments, Cibertec, Madrid), as previously described [40] . The chamber was filled with Krebs solution (composition in mmol/L: NaCl, 118; KCl, 4.75; NaHCO 3 , 25; MgSO 4 , 1.2; CaCl 2 , 2; KH 2 PO 4 , 1.2; and glucose, 11) at 37 ∘ C and gassed with 95% O 2 and 5% CO 2 . Rings were stretched to 2 g of tension and equilibrated for 90-120 min. After equilibration, aortic rings with a functional endothelium were contracted with phenylephrine (1 mol/L) and a concentration-response curve was constructed by cumulative addition of acetylcholine (basal curve). Then, to evaluate the inhibition of eNOS activity, the rings were washed and incubated with vehicle (DMSO), m (0.1, 0.5, 1 mmol/L), or L-NAME (N wnitro-L-arginine methyl ester hydrochloride) (1 mmol/L) for 30 min, and again a concentration-response curve to acetylcholine was constructed in phenylephrine-contracted rings. Results are expressed as percentage of phenylephrine-evoked contraction and area under curve (AUC) of the relaxant response was calculated as an index of eNOS activity. Data are expressed as the mean ± SEM and reflects the number of aortic rings from different rats.
Statistical Analysis.
Data are expressed as the mean ± SEM. Statistically significant differences between groups were calculated by Students' -test for unpaired observations or for multiple comparisons. ANOVA, followed by the NewmaneKeuls multiple range test, was used. A < 0.05 was considered statistically significant.
Results and Discussion
3.1. Synthetic Chemistry. The general synthetic pathways followed to obtain the new compounds a-e and a-r are represented in Schemes 1 and 2, respectively. Scheme 1 shows the general synthetic pathway of the final 5-(2-amino-5-phenylsubstituted)-2,2-dimethyl-Nsubstituted-1,3,4-thiadiazole-3(3H)-carboxamide derivatives a-e described in the present report. We have introduced two principal modifications in these derivatives in order to obtain structure-activity relationships: (i) introduction of an electron-donating group at the H-5 place of the benzene ring and (ii) insertion of an alkyl or aryl carboxamide moiety in the 3-position of the heterocyclic. The synthetic pathway begins with the esterification of the commercial 5-methoxy-2-nitrobenzoic acid which leads to the ethyl benzoate [31] . This one and the ethyl 2-nitrobenzoate were transformed into the 2-nitro-5-substituted-benzohydrazides -in the presence of hydrazine and ethanol [31] . These two molecules were turned into the corresponding 2-nitro-5-substituted-N -(1-isopropylidene)benzohydrazides -in presence of acetone and ethanol at room temperature. The subsequent addition of Lawesson's Reagent to the hydrazides led to the cyclation, obtaining the 2,3-dihydro-1,3,4-thiadiazole derivatives - [31] . Nucleophilic addition of alkyl or arylisocyanate to these last compounds using microwave gave the nitrophenyl thiadiazole-carboxamides a-e [37] , which were subjected to reduction in the presence of stannous chloride in refluxing ethanol [38] to give the desired aminoaryl thiadiazole-carboxamides a-e. On the other hand, Scheme 2 represents the synthetic pathway of the final 3-(2-amino or 6-aminophenylsubstituted)-N-substituted-4,5-dihydro-1H-pyrazole-1-carboxamide or carbothioamide derivatives. In these molecules, three major modifications have been made: (i) substitution of one, two, or three hydrogen atoms in the aromatic ring by electron-withdrawing or electrondonating groups; (ii) introduction of a carboxamide or carbothioamide moiety in the 1-position of pyrazoline heterocycle; and (iii) insertion of an alkyl or aryl substituent in the carboxamide or carbothioamide rest. In the synthesis of these compounds we have carried out the transformation of the commercially available 5-chloro-2-nitrobenzaldehyde , 5-methoxy-2-nitrobenzaldehyde , 4,5-dimethoxy-2-nitrobenzaldehyde , and the synthesized 2,3,4-trimethoxy-6-nitrobenzaldehyde (by nitration of 2,3,4-trimethoxybenzaldehyde with a mixture of HNO 3 and AcOH), into the corresponding allylic alcohols -, by treatment with vinyl-magnesium bromide [16, 32] . These intermediates were further oxidized (Jones reagent) obtaining the enone derivatives - [16, 32] . The reaction of the enones with hydrazine in ethanol produced the 4,5-dihydro-1H-pyrazoles - [16, 32] which, in situ, were converted into the intermediate nitroderivatives a-r by reaction with the adequate alkyl or aryl-isocyanates and -isothiocyanates [37] . Finally, reduction of the nitro group with SnCl 2 [38] in ethanol gave the final carboxamides and carbothioamides a-r.
Biological Assays
nNOS and iNOS Inhibition.
The in vitro biological evaluation of the new heterocycles a-e and a-r as inhibitors of both inducible and neuronal NOS isoforms has been made in the presence of recombinant isoenzymes. We have used a 1 mM concentration for each final compound. The results of this assessment are shown in Table 1 . The pyrazoline a (R 1 = 2,3,4-(OMe) 3 ; R 2 = Ph) previously published [16] has been used as a control.
The nNOS inhibition shows that the tested molecules display a moderate inhibition percentage versus this isoform, excepting the thiadiazolines a-c which exhibit considerable inhibition results. On the whole, thiadiazolines are better inhibitors than pyrazolines, being thiadiazolines with R 1 = H more potent that those with R 1 = OMe. In this way, the thiadiazole-carboxamides a (X = O, Y = S, R 2 = Et, 74.11%) and c (X = O, Y = S, R 2 = Ph, 67.02%) are the best nNOS inhibitors in this series as well as the best ones of all synthesized compounds. In addition, among pyrazoline derivatives, carbothioamides are better nNOS inhibitors than carboxamides. Within the carbothioamides, molecules with three methoxy electron-donating groups in the phenyl moiety ( o-r) are those with the best inhibition values, r (R 2 = Ph, 47.12%) being the best inhibitor of this group. In this last series, the inhibition percentage increases when the volume of the substituent in the carbothioamide moiety rises, in the Me < Et < Pr < Ph order.
Concernig the iNOS inhibition, the assayed derivatives show better results versus this inducible isoenzyme, because half of the tested molecules have more than 50% of inhibition percentage. As a rule, aryl-pyrazolines exhibit better percentages than aryl-thiadiazolines, showing inhibition percentages in the range of 50.92% and 76.86%. Among molecules with a thiadiazoline moiety, compounds with a methoxy substituent in the aromatic ring (R 1 ) show better percentages of inhibition than the unsubstituted ones, because the only two synthesized derivatives d and e have more than 50% of inhibition; and, regarding the R 2 substituent in the carboxamide residue, propyl is the best one, derivative b being the best iNOS inhibitor of this group (58.07%). With respect to the pyrazoline derivatives, about the aromatic ring substitution, the monosubstituted derivatives with an electron-withdrawing group show better iNOS inhibition values than the ones with an electron-donating group. Besides, disubstituted compounds with two donating groups produce lower inhibition than the trisubstituted derivatives. Moreover, there is not much difference between carboxamides and carbothioamides; but for the R 1 and R 2 substituents, we can see that compounds with the best inhibition values carry three electron-donating groups on the benzene ring and a propyl substituent in the carbothioamide ( q, 71.29%) or carboxamide ( m, 76.86%) residues, this last molecule being the best inhibitor of this series and the most powerful of all tested compounds. In addition, these compounds show a moderate selectivity iNOS/nNOS. If we compare derivatives and with the previously synthesized -molecules (Figure 3) , we can see that * * * * * * * * * * thiadiazoline-carboxamides are better nNOS inhibitors than acyl-thiadiazolines which had better iNOS inhibition values, although a general rule cannot be established. In addition, pyrazoline-carboxamides and carbothioamides inhibit better iNOS than nNOS unlike the acyl-pyrazolines . As a consequence, the type of substituent in the heterocyclic ring seems to be important in order to inhibit one isoform or another. Regarding the more flexible derivatives and , the new molecules behave like the 3-oxopropyl-alkylureas and thioureas due to the fact that they are also better iNOS inhibitors, unlike the derivatives with a hydroxyl group (which exhibit better nNOS inhibition values). Table 2 exhibits the IC 50 data for the nNOS inhibition of the most interesting thiadiazolines a-c, and the IC 50 data for the iNOS inhibition of the best pyrazolines b, m, q, and r, and the IC 50 value of nNOS for the control a [16] . Compound a behaves as the best nNOS inhibitor (420 M), and m had the best result versus iNOS (130 M).
eNOS Inhibition.
In addition, the best iNOS inhibitor derivative m was tested as an eNOS inhibitor in order to check the absence of side effects that could derive from the inhibition of this last isoform. In this way, acetylcholine-induced endothelium-dependent relaxation has been analyzed using endothelium intact rat aortic rings. This classic cholinergic agonist activates eNOS using a calcium-dependent mechanism [41] . Vehicle of m (DMSO) was unable to alter the relaxant responses to acetylcholine as compared to basal. Similarly, m at 0.1 and 0.5 mmol/L did not modify this response. However, m at 1 mmol/L significantly inhibited the relaxation induced by acetylcholine, whereas the nonselective NOS inhibitor L-NAME [42] suppressed this relaxant response (Figure 4(a) ). When we measured the area under curve of relaxation to acetylcholine, considered as an indirect index of eNOS activity, we found that m inhibited by 33.1% this activity at 1 mmol/L (Figure 4(b) ), confirming that this compound did not inhibit eNOS in the range 100-500 M, although it displayed a poor eNOS inhibitory effect to higher concentration.
Conclusions
In summary, the synthesis of five new thiadiazoline-and eighteen pyrazoline-based carboxamides and carbothioamides and , each one with different substituents in the aromatic ring and in the carboxamide or carbothioamide moiety, is described. Furthermore, we evaluate the nNOS and iNOS Table 2 : IC 50 values (mM) for the inhibition of nNOS activity of compounds a-c and iNOS activity of b, m, q, and r. Pyrazoline a has been included as a control [16] . inhibitory activity of all these new derivatives and the eNOS activity for the best iNOS inhibitor m. In general, thiadiazolines are better nNOS inhibitors and pyrazolines present better inhibition against iNOS versus nNOS, carbothioamides being with three donating substituents in the aromatic ring the best ones. Thiadiazoline-carboxamide a is the most powerful nNOS inhibitor tested, and pyrazolinecarbothioamide m is the best iNOS of all them all. In addition, this last compound is approximately 2.5 times more selective to inhibit NOS in inflammatory processes than the constitutive nNOS. Moreover, m does not inhibit eNOS at the concentration values necessary to inhibit the other isoforms, which is convenient in order to avoid hypertension as a side effect. Consequently, these novel derivatives could be an interesting starting point to find possible new therapeutic alternatives for neurodegenerative and inflammatory diseases.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
